Strafford will be offering a webinar entitled "Biologics and Biosimilars: FDA Initiatives and Guidance, Approvals and Exclusivity, Patent Prosecution, Litigation" on January 22, 2019 from 1:00 to 2:30 pm (EST). Shana K. Cyr and Mark J. Feldstein of Finnegan Henderson Farabow Garrett & Dunner and Kurt R. Karst of Hyman Phelps & McNamara will provide essential updates on FDA practice and patent law relating to biologics and biosimilars, and will discuss the current state of and recent changes to FDA initiatives, approvals and exclusivities, as well as patent prosecution, post-grant proceedings and litigation. The webinar will review the following issues:
• What can we learn from FDA's recent guidance on biologics and biosimilars?
• How does FDA's recent guidance impact patent strategy?
• Should your patent strategy for biologics differ from your approach for small molecule drugs?
The registration fee for the webcast is $297. Those interested in registering for the webinar, can do so here.
Comments